PTEN and intrahepatic cholangiocarcinoma: Bortezomib displayed encouraging efficacy with manageable toxicities as a second‐line therapy for patients with PTEN‐deficient ICC, significantly prolonging OS to a median of 9.6 months in the PP cohort.